FFHL vs SBTX

Fuwei Films (Holdings) Co. Ltd.

Fuwei Films (Holdings) Co., Ltd., through its subsidiaries, engages in the development, manufacture, and distribution of biaxially oriented polyethylene-terephthalate films in the People's Republic of China. The company offers dry film, which is used in circuit boards production, nameplate, and crafts etching; chemically treated films used to enhance properties, such as barrier resistance, printing properties, and electrostatic resistance; stamping foil base films and transfer base films for packaging of luxury items, including cigarettes and alcohol; and printing base films for use in printing and lamination. It also provides metallized films or aluminum plating base films for use in vacuum aluminum plating for flexible plastic lamination; high-gloss films for aesthetically enhanced packaging purposes; heat-sealable films for construction, printing, and making heat sealable bags; and laser holographic base films used as anti-counterfeit films for food, medicine, cosmetics, cigarettes, and alcohol packaging; and heat shrinkable films used for special-shaped packaging for beverage and cosmetics. The company markets and sells its products under Fuwei Films brand for packaging, imaging, electronics, electrical, and magnetic products. It also exports its products to end-users and distributors primarily in Europe, Asia, and North America. The company was formerly known as Neo-Luck Plastic Holdings Co., Ltd. and changed its name to Fuwei Films (Holdings) Co., Ltd. in April 2005. The company was founded in 2003 and is headquartered in Weifang, the People's Republic of China. Fuwei Films (Holdings) Co., Ltd. is a subsidiary of Hongkong Ruishang International Trade Co., Ltd.

Silverback Therapeutics Inc.

Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.